Sermorelin Dosage Guide

Age-based protocols for the original GHRH analog — bedtime dosing, reconstitution, injection technique, stacking with Ipamorelin & CJC-1295, cycling, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

What Is Sermorelin?

Sermorelin acetate is the biologically active fragment of human growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids (GRF 1-29). It is the natural GHRH sequence — unlike CJC-1295 (Mod GRF 1-29), which has amino acid substitutions to extend its half-life. Sermorelin was the first growth hormone-releasing hormone therapy to receive FDA approval, in 1997 under the brand name Geref.

While newer peptides like CJC-1295 and Ipamorelin have since gained popularity, Sermorelin remains widely used in clinical anti-aging medicine due to its established safety record, regulatory history, and the fact that it was specifically designed for age-related GH decline. What makes Sermorelin unique is the age-based dosing approach — GH output declines approximately 14% per decade after age 30, and Sermorelin protocols are typically adjusted based on the patient's age and baseline GH/IGF-1 levels.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from clinical studies, published research, and community protocols.

Key Characteristics:

Natural GHRH sequence — identical to the first 29 amino acids of endogenous human growth hormone-releasing hormone
Short half-life (~10–20 minutes) — rapidly cleared from circulation, producing a discrete, physiological GH pulse rather than sustained elevation
Pituitary-dependent — requires a functioning pituitary gland to work; stimulates the pituitary to produce and release its own growth hormone
FDA history — previously FDA-approved as Geref (1997); discontinued 2008 for commercial reasons, not safety
Age-appropriate — particularly suited to addressing age-related GH decline with dose adjustments based on patient age
Bedtime dosing — most effective when aligned with the natural nocturnal GH secretion pattern during deep sleep

For a complete overview of its mechanism and research, see our full Sermorelin profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Sermorelin Dosage Is Determined

Sermorelin dosing — expressed in micrograms (mcg) per injection at bedtime — is derived from FDA-approved therapeutic protocols, age-based clinical practice standards, and decades of practitioner experience in anti-aging medicine. Unlike most research peptides, Sermorelin has a regulatory history that provides a stronger dosing foundation.

FDA-Approved Dosing (Historical)

Geref was FDA-approved for the diagnosis of growth hormone deficiency. The therapeutic dosing range established during clinical use was 200–500 mcg administered subcutaneously at bedtime. This range served as the foundation for current anti-aging protocols.

Age-Based Approach

GH production declines with age — approximately 14% per decade after age 30. By age 60, most individuals produce less than half the GH they did at 25. Sermorelin protocols account for this by adjusting dose upward for older patients, who have reduced pituitary responsiveness and lower baseline GH/IGF-1 levels.

Clinical Practice Standards

The American Academy of Anti-Aging Medicine (A4M) has established protocols based on decades of clinical use. These protocols incorporate IGF-1 monitoring to guide dose adjustments, with the goal of restoring IGF-1 levels to the upper-normal range for the patient's age.

Strength of evidence: Strong. Sermorelin has an FDA-approved history, multiple published clinical studies in both adults and children, and decades of clinical use in anti-aging medicine. Dosing protocols are based on established therapeutic ranges rather than extrapolation from animal studies alone.

Standard Sermorelin Dosage Ranges

Sermorelin is administered subcutaneously at bedtime, on an empty stomach. The following table summarizes the standard dosing tiers used in clinical anti-aging practice.

Level	Dose	Frequency	Notes
Conservative	100–200 mcg	Bedtime daily	Starting dose; suitable for younger patients (30s) or dose assessment
Standard	200–300 mcg	Bedtime daily	Most common clinical dose; effective for most anti-aging protocols
Aggressive	300–500 mcg	Bedtime daily	Higher-dose clinical protocols; typically for patients 50+ or with low baseline IGF-1

Dosage Selection: Most patients start at 200–300 mcg at bedtime daily. The dose is then adjusted based on IGF-1 blood test results at 6–8 weeks. The goal is to bring IGF-1 into the upper-normal range for the patient's age. If IGF-1 remains low, the dose is increased. If IGF-1 exceeds the target range, the dose is reduced.

Verified sources for Sermorelin

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChemsThird-party tested research peptides10% off

SwissChems10% off

Limitless BiotechPremium nootropics & research peptides15% off

Limitless Biotech15% off

CH PeptidesResearch-grade peptides with COA transparency10% off

CH Peptides10% off

View all vendor deals·Affiliate links. Commission at no extra cost.

Age-Based Sermorelin Dosage Chart

Because GH output declines with age, Sermorelin protocols are typically adjusted based on the patient's age bracket. Older patients generally require higher doses to achieve the same level of pituitary stimulation. The following chart reflects standard clinical practice.

Age Range	Starting Dose	Maintenance Dose	Notes
30–39	100–200 mcg	200 mcg bedtime	Mild GH decline; may respond quickly to lower doses
40–49	200–300 mcg	300 mcg bedtime	Standard anti-aging starting point; most common age group
50–59	300 mcg	300–500 mcg bedtime	Higher dose often needed due to reduced pituitary output
60–69	300–500 mcg	300–500 mcg bedtime	Pituitary responsiveness decreasing; monitor IGF-1 closely
70+	500 mcg	500 mcg bedtime	Maximum dose; requires close medical monitoring

Age-Based Adjustment: These are starting guidelines, not rigid rules. Individual response varies significantly based on baseline IGF-1 levels, overall health, body composition, and pituitary function. Always confirm dose adequacy with IGF-1 blood tests at 6–8 week intervals and adjust accordingly.

Calculate Your Sermorelin Dose

Sermorelin is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 15 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 5 mg (5,000 mcg) of Sermorelin
Bacteriostatic water added: 2.5 mL
Concentration: 5,000 mcg ÷ 2.5 mL = 2,000 mcg per mL
Target dose: 300 mcg
Volume to draw: 300 ÷ 2,000 = 0.15 mL = 15 units on an insulin syringe

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	300 mcg Dose	Doses per Vial
1 mL	5,000 mcg/mL	6 units (0.06 mL)	~16 doses
2 mL	2,500 mcg/mL	12 units (0.12 mL)	~16 doses
2.5 mL	2,000 mcg/mL	15 units (0.15 mL)	~16 doses
5 mL	1,000 mcg/mL	30 units (0.30 mL)	~16 doses

Skip the Math — Use Our Sermorelin

Enter your Sermorelin vial size, water volume, and desired dose — get instant calculations with zero manual math.

How to Reconstitute Sermorelin

Sermorelin comes as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. This process is straightforward but requires clean technique to maintain sterility and peptide integrity.

Supplies Needed:

Sermorelin lyophilized vial (5 mg or 15 mg)
Bacteriostatic water (BAC water) — contains 0.9% benzyl alcohol as preservative
Insulin syringes (29–31 gauge, 0.5 mL or 1 mL) for injection
Alcohol swabs (70% isopropyl alcohol)
Clean, flat workspace
Optional: larger syringe (1–3 mL) for drawing bacteriostatic water if using a separate drawing needle

Steps

Wash Hands & Prepare Workspace

Wash hands thoroughly with soap and water. Lay out supplies on a clean surface: Sermorelin vial, bacteriostatic water, insulin syringe, and alcohol swabs.

Remove the Vial Caps

Flip off the plastic caps from both the Sermorelin vial and the bacteriostatic water vial. Swab both rubber stoppers with alcohol pads and let them air-dry for 10–15 seconds.

Draw Bacteriostatic Water

Using a fresh insulin syringe, draw your desired volume of bacteriostatic water. For a 5 mg vial, 2.5 mL is a common choice (yields 2,000 mcg per mL / 300 mcg per 15 units).

Add Water to the Peptide Calculator Vial

Insert the needle into the Sermorelin vial through the rubber stopper. Angle the needle so the water runs down the inside glass wall — never squirt directly onto the powder cake. Release the plunger slowly.

Dissolve Gently

Remove the syringe. Let the vial sit for 1–2 minutes, then gently swirl or roll between your palms until the powder is fully dissolved. The solution should be clear and colorless. Never shake.

Label & Refrigerate

Write the reconstitution date and concentration on the vial. Store refrigerated at 2–8°C. Use within 3–4 weeks.

Storage

Unreconstituted (powder): Store refrigerated (2–8°C) for maximum shelf life; room temperature is acceptable for short periods but reduces potency over time
Reconstituted (in bacteriostatic water): Must be refrigerated at 2–8°C; use within 3–4 weeks
Do not freeze: Freezing reconstituted Sermorelin can damage the peptide structure through ice crystal formation
Protect from light and heat — keep the vial in its box or wrapped in foil, away from direct sunlight and temperatures above 25°C

For a detailed visual walkthrough, see our Reconstitution Guide.

Sermorelin Dosage by Goal

While Sermorelin's core mechanism — stimulating pituitary GH release — is consistent, the optimal dosing protocol varies by the specific goal and patient context. All protocols use bedtime subcutaneous injection on an empty stomach.

Anti-Aging / GH Optimization

The most common application. Sermorelin restores declining GH levels to a more youthful range, supporting skin quality, body composition, energy, cognitive function, and overall vitality. IGF-1 monitoring is essential to guide dose adjustments.

Dose: 200–300 mcg at bedtime
Frequency: Daily or 5 days per week
Duration: 3–6 months on, 1–2 months off
Monitoring: IGF-1 blood test at baseline and every 6–8 weeks

Sleep Quality

Improved sleep quality is often the first noticeable benefit of Sermorelin therapy, typically within 1–2 weeks. GH is intimately linked to sleep architecture — the largest natural GH pulse occurs during slow-wave (deep) sleep. Sermorelin amplifies this pulse, enhancing sleep depth and recovery.

Dose: 200 mcg at bedtime
Frequency: Daily
Duration: Ongoing with periodic breaks
Notes: Lower doses are often sufficient for sleep benefits alone

Body Composition

For body composition improvement — reducing visceral fat and supporting lean muscle mass — higher doses and longer duration are typically required. Results are gradual and require consistent daily dosing combined with appropriate exercise and nutrition.

Dose: 300–500 mcg at bedtime
Frequency: Daily
Duration: 3–6 months
Notes: Combine with resistance training for best results; monitor IGF-1

Post-Injury Recovery

Elevated GH levels support tissue repair, collagen synthesis, and overall recovery from injury. Some practitioners combine Sermorelin with tissue-specific peptides like BPC-157 or TB-500 for comprehensive recovery support.

Dose: 300 mcg at bedtime
Frequency: Daily
Duration: 8–12 weeks
Notes: Often combined with BPC-157 or TB-500 for targeted tissue repair

Application Tip: Consistency is critical with Sermorelin. The peptide works by gradually restoring pituitary GH output over weeks and months. Skipping doses or inconsistent timing reduces effectiveness. Inject at the same time each night, on an empty stomach, for best results.

Sermorelin Injection Guide

Subcutaneous (SubQ) Injection — Step by Step

Wash Hands

Wash hands thoroughly with soap and water. Prepare a clean workspace with your syringe, alcohol swab, and reconstituted Sermorelin vial.

Swab the Vial Stopper

Wipe the rubber stopper of the Sermorelin vial with an alcohol swab. Let it air-dry for 10–15 seconds.

Draw Your Dose

Pull back the plunger to draw air equal to your dose volume. Insert the needle into the vial, push in the air, invert the vial, and slowly draw out your calculated dose. Tap out any air bubbles.

Choose the Injection Site

The lower abdomen (2–3 inches from the navel) is the most common injection site. The upper thigh is an alternative. Rotate injection sites to avoid irritation.

Clean the Injection Site

Swab the chosen injection site with a fresh alcohol pad. Allow to air-dry completely before injecting.

Inject

Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 45-degree angle into the pinched skin fold. Push the plunger slowly and steadily. Withdraw the needle and apply light pressure with the alcohol swab if needed.

Dispose Safely

Place the used syringe immediately into a sharps container. Never recap or reuse needles.

Timing Rules

Inject at bedtime — 30 minutes before sleep to synergize with the natural nocturnal GH pulse
Empty stomach required — at least 2 hours after your last meal; food and insulin blunt the GH response
No late snacking — if you eat after injecting, the GH pulse is significantly reduced
Consistent timing — inject at the same time each night for best results

Key rule: Inject subcutaneously in the abdomen or thigh at bedtime on an empty stomach. The combination of bedtime timing and fasted state is critical for maximizing Sermorelin's GH-releasing effect.

Sermorelin Cycle Duration & Timing

Sermorelin is typically used in defined cycles with periodic breaks, though some patients under physician supervision use it continuously with regular lab monitoring. Cycling allows assessment of progress and prevents potential desensitization of the pituitary GHRH receptor.

Protocol	Duration	Frequency	Notes
Standard anti-aging	3 months on, 1 month off	Bedtime daily	Most common cycling pattern; reassess IGF-1 during off-period
Extended body composition	6 months on, 2 months off	Bedtime daily	For body composition goals requiring longer duration
Continuous (clinical)	Ongoing with periodic labs	Bedtime daily or 5 days/week	Under physician supervision with IGF-1 monitoring every 3–6 months

Timing Considerations

Always bedtime: Sermorelin must be injected at bedtime to synergize with the natural nocturnal GH pulse. This is not optional.
Fasted for 2+ hours: No food for at least 2 hours before injection. Insulin suppresses GH release.
5 days/week option: Some protocols use daily dosing Monday through Friday with weekends off to reduce injection burden while maintaining most of the benefit.
Lab monitoring: Test IGF-1 at baseline, 6–8 weeks, and then every 3–6 months to guide dose adjustments.

Sermorelin Stacking Protocols

Sermorelin is frequently combined with other GH-releasing peptides to amplify the growth hormone response. The most effective stacks combine GHRH analogs (like Sermorelin) with ghrelin receptor agonists (like Ipamorelin) to stimulate GH release through complementary pathways.

Sermorelin + Ipamorelin (GHRH + GHRP — Dual-Pathway GH Release)

The most popular Sermorelin stack. Sermorelin stimulates GH release via the GHRH receptor on the pituitary, while Ipamorelin stimulates GH release via the ghrelin (GHS) receptor. Together, they produce a significantly larger GH pulse than either peptide alone — the two pathways are synergistic, not merely additive.

Compound	Dose	Frequency	Purpose
Sermorelin	200–300 mcg SubQ	Bedtime daily (fasted)	GHRH receptor stimulation; initiates GH release pulse
Ipamorelin	200 mcg SubQ	Bedtime daily (same session)	Ghrelin receptor agonist; amplifies GH pulse, minimal side effects

Protocol note: Both peptides can be injected at the same time in separate syringes (or drawn into the same syringe if your provider approves). Inject at bedtime on an empty stomach. This combination is widely regarded as one of the safest and most effective GH-releasing stacks available.

Sermorelin + CJC-1295 (no DAC) + Ipamorelin (Triple GH Stack)

For users seeking maximum GH optimization, adding CJC-1295 (Mod GRF 1-29, no DAC) provides an additional GHRH analog with a slightly longer half-life. Sermorelin is used at bedtime only, while CJC-1295 and Ipamorelin can be used at additional fasted time points during the day for more frequent GH pulses.

Compound	Dose	Frequency	Purpose
Sermorelin	200 mcg SubQ	Bedtime only (fasted)	Natural GHRH pulse at bedtime
CJC-1295	100 mcg SubQ	2–3x daily (fasted)	Modified GHRH with longer half-life for daytime GH pulses
Ipamorelin	200 mcg SubQ	2–3x daily (fasted)	Ghrelin receptor agonist to amplify each GH pulse

This triple stack is the most aggressive GH-releasing protocol and is typically used by experienced users under medical supervision. CJC-1295 and Ipamorelin are injected together at fasted time points (e.g., morning, pre-workout, bedtime), with Sermorelin added at the bedtime dose only.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Sermorelin has one of the strongest safety records among GH-releasing peptides, backed by its FDA-approved history as Geref and decades of clinical use. It stimulates natural GH production through the pituitary rather than introducing exogenous growth hormone, making it inherently safer than direct GH administration. Side effects are generally mild and uncommon.

Common Side Effects

Mild and generally transient (reported by a minority of patients):

Injection site irritation — redness, soreness, or minor swelling at the injection site
Flushing — temporary warmth or redness of the face and neck
Headache — typically mild and short-lived
Dizziness — occasionally reported, usually transient
Drowsiness — can occur shortly after injection, which is actually appropriate given bedtime dosing

Key point: Because Sermorelin stimulates the pituitary to produce its own GH (rather than administering exogenous GH), the body's natural feedback mechanisms remain intact. This makes GH overproduction unlikely — the pituitary will not release more GH than the feedback loop allows.

Contraindications

Active cancer or history of cancer — elevated GH and IGF-1 levels may theoretically promote tumor growth. Sermorelin should not be used in patients with active malignancies.
Pregnancy and breastfeeding — no safety data exists for Sermorelin during pregnancy or nursing. Avoid use entirely.
Pituitary tumors — stimulating a pituitary with an existing tumor could exacerbate the condition. Requires clearance from an endocrinologist.
Diabetes (monitor closely) — GH can affect insulin sensitivity and blood glucose levels. Diabetic patients require close monitoring of blood sugar when using Sermorelin.
Uncontrolled hypothyroidism — thyroid function affects GH metabolism. Hypothyroidism should be adequately treated before starting Sermorelin therapy.

When to Stop

Persistent headaches or dizziness that do not resolve within the first week
Signs of fluid retention — unusual swelling in extremities, carpal tunnel symptoms
Joint pain or stiffness (may indicate IGF-1 levels are too high)
Any symptom that feels unusual or concerning — consult your healthcare provider

Regulatory Status: Sermorelin was previously FDA-approved as Geref (approved 1997, voluntarily discontinued 2008 for commercial reasons). It is currently available through compounding pharmacies. It is prohibited by WADA (World Anti-Doping Agency) for competitive athletes. Always use under medical supervision.

Common Sermorelin Dosing Mistakes

Avoid these common errors to get the most out of your Sermorelin protocol:

Injecting in the morning instead of at bedtime: Sermorelin is designed to amplify the natural nocturnal GH pulse that occurs during deep sleep. Morning injection misses this physiological window and produces a less effective GH response.

Injecting after a late meal: Eating within 2 hours of injection elevates blood glucose and insulin, which directly inhibits GH release. Always inject on an empty stomach — at least 2 hours after your last meal.

Not adjusting dose for age: GH output declines approximately 14% per decade after age 30. A dose appropriate for a 35-year-old may be insufficient for a 60-year-old. Use the age-based dosing chart and monitor IGF-1 levels.

Expecting rapid results: Sermorelin works gradually by stimulating your own pituitary to produce more GH. Sleep improvements may appear in 1–2 weeks, but body composition and anti-aging benefits typically require 3–6 months of consistent daily dosing.

Not monitoring IGF-1 levels: IGF-1 is the primary biomarker for assessing GH status. Without periodic blood tests, you cannot objectively determine whether your Sermorelin dose is effective or needs adjustment. Test at baseline and every 6–8 weeks.

Stopping the protocol too soon: Many users discontinue after 4–6 weeks because they have not yet seen body composition changes. Sermorelin requires a minimum of 3 months for meaningful anti-aging results. Give the protocol adequate time before evaluating.

Frequently Asked Questions

Key Takeaways

Standard dose: 200–300 mcg SubQ at bedtime, daily — the most common clinical anti-aging protocol
Bedtime dosing is critical — Sermorelin must be injected at bedtime on an empty stomach to synergize with the natural nocturnal GH pulse
Age-based protocols — older patients typically need higher doses (300–500 mcg) due to declining pituitary responsiveness
Previously FDA-approved (Geref) — one of the strongest safety records among GH-releasing peptides
Monitor IGF-1 to guide dosing — test at baseline and every 6–8 weeks to confirm dose adequacy
Results take 3–6 months — sleep may improve in 1–2 weeks, but body composition and anti-aging benefits require patience
Top stack: Sermorelin + Ipamorelin at bedtime for synergistic GH release through complementary GHRH and ghrelin pathways
Pituitary-dependent — stimulates your own GH production rather than introducing exogenous growth hormone, preserving natural feedback mechanisms
Fasting required — at least 2 hours after last meal; insulin suppresses GH release
Store reconstituted vials refrigerated at 2–8°C and use within 3–4 weeks

This article is for educational and informational purposes only. See our Disclaimer.

References

Corpas E, et al. “Human growth hormone and human aging.” Endocr Rev. 1993;14(1):20-39. PubMed
Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging. 2006;1(4):307-314. PubMed
Merriam GR, et al. “Growth hormone-releasing hormone treatment in normal aging.” J Anti-Aging Med. 2001;4(4):331-343.
Vittone J, et al. “Effects of single nightly injections of GHRH 1-29 in healthy elderly men.” Metabolism. 1997;46(1):89-96. PubMed

Next Steps

Continue your research with these resources.

CJC-1295 Dosage Guide

Learn dosing protocols for CJC-1295 (Mod GRF 1-29), Sermorelin’s modified-sequence counterpart.

Read Guide

Dosage Calculator

Calculate your exact Sermorelin dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory